<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nondiabetic <z:mp ids='MP_0001261'>obese</z:mp> humans adapt to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> by increasing beta-cell mass </plain></SENT>
<SENT sid="1" pm="."><plain>In contrast, <z:mp ids='MP_0001261'>obese</z:mp> humans with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have an approximately 60% deficit in beta-cell mass </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies in rodents reveal that beta-cell mass is regulated, increasing in response to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> through increased beta-cell supply (islet neogenesis and beta-cell replication) and/or decreased beta-cell loss (beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath>) </plain></SENT>
<SENT sid="3" pm="."><plain>Prospective studies of islet turnover are not possible in humans </plain></SENT>
<SENT sid="4" pm="."><plain>In an attempt to establish the mechanism for the deficit in beta-cell mass in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we used an <z:mp ids='MP_0001261'>obese</z:mp> versus lean murine <z:e sem="disease" ids="C1519606" disease_type="Experimental Model of Disease" abbrv="">transgenic model</z:e> for human islet amyloid <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (IAPP) that develops islet pathology comparable to that in humans with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>By 40 weeks of age, <z:mp ids='MP_0001261'>obese</z:mp> nontransgenic mice did not develop <z:mp ids='MP_0002055'>diabetes</z:mp> and adapted to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> by a 9-fold increase (P &lt; 0.001) in beta-cell mass accomplished by a 1.7-fold increase in islet neogenesis (P &lt; 0.05) and a 5-fold increase in beta-cell replication per islet (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0001261'>Obese</z:mp> transgenic mice developed midlife <z:mp ids='MP_0002055'>diabetes</z:mp> with islet amyloid and an 80% (P &lt; 0.001) deficit in beta-cell mass that was due to failure to adaptively increase beta-cell mass </plain></SENT>
<SENT sid="7" pm="."><plain>The mechanism subserving this failed expansion was a 10-fold increase in beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>There was no relationship between the extent of islet amyloid or the blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration and the frequency of beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>However, the frequency of beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was related to the rate of increase of islet amyloid </plain></SENT>
<SENT sid="10" pm="."><plain>These prospective studies suggest that the formation of islet amyloid rather than the islet amyloid per se is related to increased beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in this murine model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>This finding is consistent with the hypothesis that soluble IAPP oligomers but not islet amyloid are responsible for increased beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="12" pm="."><plain>The current studies also support the concept that replicating beta-cells are more vulnerable to <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, possibly accounting for the failure of beta-cell mass to expand appropriately in response to <z:hpo ids='HP_0001513'>obesity</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>